Young patients with non-germinal center B-cell - like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: Analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association phase III trial LNH 03-2B

Journal of Clinical Oncology

Volumn 32, Issue 35, 2014, Pages 3996-4003

  Jo Molina, Thierry ^a   Canioni, Danielle ^a   Copie Bergman, Christiane ^b,c   Recher, Christian ^d   Brière, Josette ^b   Haioun, Corinne ^b   Berger, Franҫoise ^e   Fermé, Christophe ^f   Copin, Marie Christine ^g   Casasnovas, Olivier ^h   Thieblemont, Catherine ^b,c   Petrella, Tony ^h   Leroy, Karen ^b,c   Salles, Gilles ^e   Fabiani, Bettina ^b   Morschauser, Franck ^g   Mounier, Nicolas ⁱ   Coiffier, Bertrand ^e   Jardin, Fabrice ^j   Gaulard, Philippe ^b,c   Jais, Jean Philippe ^a   Tilly, Hervé ^h   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ LYON 1   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NICE   (France)

^j UNIVERSITÉ DE ROUEN   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; VINDESINE; BCL6 PROTEIN, HUMAN; CCL2 PROTEIN, HUMAN; DNA BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; MEMBRANE METALLOENDOPEPTIDASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN, HUMAN; PREDNISOLONE; R-CHOP PROTOCOL; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ALGORITHM; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHEMOKINE CCL2; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON REGULATORY FACTORS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PREDNISOLONE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; VINDESINE;

EID: 84919343441     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.9493     Document Type: Article

References (34)

1. Swerdlow SH, Campo E, Harris NL, et al: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France IARC Press, 2008
2. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
3. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
4. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
5. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005
6. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
7. Delarue R, Tilly H, Mounier N, et al: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol 14:525-533, 2013
8. Cunningham D, Hawkes EA, Jack A, et al: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381: 1817-1826, 2013
9. Récher C, Coiffier B, Haioun C, et al: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 378: 1858-1867, 2011
10. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
11. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
12. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002
13. Jais JP, Haioun C, Molina TJ, et al: The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22:1917-1924, 2008
14. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
15. Meyer PN, Fu K, Greiner TC, et al: Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29: 200-207, 2011
16. Fu K, Weisenburger DD, Choi WW, et al: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
17. Salles G, de Jong D, Xie W, et al: Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117:7070-7078, 2011
18. Copie-Bergman C, Gaulard P, Leroy K, et al: Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: A GELA study. J Clin Oncol 27:5573-5579, 2009
19. Gutiérrez-García G, Cardesa-Salzmann T, Climent F, et al: Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 117:4836-4843, 2011
20. Ott G, Ziepert M, Klapper W, et al: Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116:4916-4925, 2010
21. Johnson NA, Slack GW, Savage KJ, et al: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3452-3459, 2012
22. Green TM, Young KH, Visco C, et al: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460-3467, 2012
23. Horn H, Ziepert M, Becher C, et al: MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253-2263, 2013
24. Wilson WH, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008
25. Wilson WH, Jung SH, Porcu P, et al: A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97:758-765, 2012
26. Young RM, Staudt LM: Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12:229-243, 2013
27. Jing H, Kase J, Dörr JR, et al: Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev 25:2137-2146, 2011
28. Reference deleted
29. Majumdar S, Aggarwal BB: Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 167:2911-2920, 2001
30. Kim A, Lee JE, Jang WS, et al: A combination of methotrexate and irradiation promotes cell death in NK/T-cell lymphoma cells via down-regulation of NF-κB signaling. Leuk Res 36:350-357, 2012
31. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690-697, 2011
32. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al: Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 117:5058-5066, 2011
33. Yang Y, Shaffer AL 3rd, Emre NC, et al: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723-737, 2012
34. Thieblemont C, Briere J, Mounier N, et al: The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study. J Clin Oncol 29:4079-4087, 2011